Print
31 March 2015
Pharmaceutical-Tech.com
Russian pharmaceutical market is developing rapidly, it takes 11th place in the rating of pharmaceutical markets' volume in the world and is predicted to go up to the 9th place by 2016. Along with growing potential, important changes in the industry take place due to governmental program “Pharma 2020”.
With all the evidence pointing at Russian rapidly developing pharma industry and quality issues being in the center, Fleming Europe has decided to organize conference on Quality Assurance in Russian Pharma Manufacturing.
Experts from Johnson & Johnson, Novartis, Bayer Healthcare, Novo Nordisk, Akrikhin, Stada CIS, Vertex, R-Pharm and others will gather on 27 – 28 May 2015 in Moscow to discuss how to ensure the level of quality and therefore: guarantee safety of drugs, lower production risks and increase sales.
During the two interactive days, attendees will have the opportunity to learn from case studies, gain the insights and learn from best practitioners, get tangible and hands-on knowledge, meet industry professionals and discover innovative approaches to quality assurance in other industries.
GMP experts and company representatives will reveal their best practices of GMP implementation and representatives from Russian regulatory bodies will provide with updates on governmental regulations. Speakers from Akrikhin will lead hands-on workshop on building risk management system, representatives from Johnson & Johnson, Bayer Healthcare and Petrovax will explain how to spread and include quality system principles into all processes of the company and much more!
About Fleming Europe
Established in Slovakia, Fleming Europe represents a Pan-European B2B networking channel for specialists to collect & share knowledge. Since 2004, the company has been encouraging decision makers in sharing their experiences through market leading conferences, trainings and webinars. The annual audience of 10,000 Banking, Defense, Energy, Oil & Gas, Pharma, Telco and Transport peers benefit from insights on industry trends when applying them to their own business practices. For more information, visit http://flemingeurope.com/
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.